Interactions of buprenorphine and selective dopamine receptor antagonists in the rat nucleus accumbens

General Pharmacology

Volumn 31, Issue 3, 1998, Pages 425-429

  Nantwi, K D ^a   Hicks, S ^a   Bradley Jr , D ^a   Schoener, E P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Dopamine antagonists; Neuronal activity; Opioid

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BUPRENORPHINE; DOPAMINE RECEPTOR BLOCKING AGENT; ETICLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; EVOKED RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE CONDUCTION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECORDING;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; BUPRENORPHINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; NARCOTICS; NEURONS; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; SALICYLAMIDES;

EID: 0032167748     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00020-2     Document Type: Article

References (51)

1. Bozarth M.A., Wise R.A. Intracranial self-administration of morphine into the ventral tegmental area of rats. Life Sci. 28:1981;551-555.
2. Bozarth M.A., Wise R.A. Actions of drugs of abuse on brain reward systems. an update with specific attention to opiates Pharmac. Biochem. Behav. 17:1982;239-243.
3. Bozarth M.A., Wise R.A. Involvement of the ventral tegmental dopamine system in opioid and psychomotor stimulant reinforcement. NIDA Res. Monog. 67:1986;190-196.
4. Broekkamp C.L.E., Phillips A.G., Cools A.R. Stimulant effects of enkephalin microinjection into dopaminergic A10 area. Nature. 278:1979;560-562.
5. Brown E.E., Finlay J.M., Wong J.T.F., Damsam G., Fibiger H.C. Behavioral and neurochemical interactions between cocaine and buprenorphine. implications for the pharmacotherapy of cocaine abuse J. Pharmac. Exp. Ther. 256:1990;119-126.
6. Cowan A., Dettmar P.W., Walker D.S. The effect of acute doses of buprenorphine on concentrations of homovanillic acid (HVA), 5-hydroxy-indoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) in the rat forebrain. Br. J. Pharmac. 58:1976;275.
7. Dahlstromm A., Fuxe K. Evidence for the existence of monoamine containing neurons in the central nervous system. 1. determination of monoamines in cell bodies of brain stem neurons Acta Physiol. Scand. 232:1964;1-25.
8. Dettmar P.W., Cowan A., Walter D.S. A comparison of the neurochemical effects of buprenorphine with those of morphine and haloperidol in rats. Eur. J. Pharmac. 69:1981;147-153.
9. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase dopamine concentrations in the mesolimbic system of freely moving rats. PNAS. 85(14):1988;5274-5278.
10. Dworkin S.I., Guerin G.F., Goeders N.E., Smith J.E. Kainic acid lesions of the nucleus accumbens selectively attenuate morphine self-administration. Pharmac. Biochem. Behav. 29:1988;175-181.
11. France C.P., Jacobson A.E., Woods J.H. Discriminative stimulus effects of reversible and irreversible opiate agonists. morphine, oxymorphazone and buprenorphine J. Pharmac. Exp. Ther. 230:1984;652-657.
12. Goeders N.E., Lane J.D., Smith J.E. Self-administration of methionine enkephalin into the nucleus accumbens. Pharmac. Biochem. Behav. 20:1984;451-455.
13. Grant S.J., Sonti G. Buprenorphine and morphine produce equivalent increases in extracellular unit activity of dopamine neurons in the ventral tegmental area in vivo. Synapse. 16:1994;181-187.
14. Hakan R.L., Henriksen S.J. Systemic opiate administration has heterogeneous effects on activity recorded from nucleus accumbens in vivo. Neurosci. Lett. 83:1987;307-312.
15. Hakan R.L., Henriksen S.J. Opiate influences on nucleus accumbens neuronal electrophysiology. dopamine and non-dopamine mechanisms J. Neurosci. 9:1989;3538-3546.
16. Hand T.H., Franklin K.B.J. 6-Hyroxydopamine lesions of the ventral tegmental area block morphine-induced but not amphetamine-induced facilitation of self-stimulation. Brain Res. 328:1985;233-241.
17. Heel R., Brodgen R., Speight T., Avery G. Buprenorphine. a review of its pharmacological properties and therapeutic efficacy Drugs. 17:1979;81-110.
18. Henry D.J., Wise R.A., Rompre P., White F.J. Acute depolarization block of A10 dopamine neurons. interactions of morphine with dopamine antagonists Brain Res. 596:1992;231-237.
19. Iorio L., Barnett A., Leitz F., Houser V., Korduba C. SCH23390. a potential benzazepine antipsychotic with unique interactions on dopaminergic systems J. Pharmac. Exp. Ther. 226:1983;462-468.
20. Jaffe J. and Martin W. R. (1990) Opioid analgesics and antagonists. In Pharmacological Basis of Therapeutics, 8th edn (Edited by Gilman A. G., Rall T. W., Nies A. S. and Taylor P.), pp. 623-657. Pergamon Press, New York.
21. Jasinski D.R., Pernick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry. 35:1978;501-516.
22. Joyce E.M., Iversen S.D. The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat. Neurosci. Lett. 14:1979;207-212.
23. Joyce E.M., Koob G.F., Strecker R., Iversen S.D., Bloom F.E. The behavioral effects of enkephalin analogues injected into the ventral tegmental area and globus pallidus. Brain Res. 221:1981;359-370.
24. Klitenick M.A., DeWitte P., Kalivas P.W. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA. an in vivo microdialysis study J. Neurosci. 12:1992;2623-2632.
25. Koob G.F. Drugs of abuse. anatomy, pharmacology, and function of reward pathways Trends Pharmac. Sci. 13:1992;177-184.
26. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 14:1991;299-303.
27. Leone P., DiChiara G. Blockade of D-1 receptors by SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning. Eur. J. Pharmac. 135:1987;251-254.
28. Leone P., Pocock D., Wise R.A. Morphine-dopamine interaction. ventral tegmental morphine increases nucleus accumbens dopamine release Pharmac. Biochem. Behav. 39:1991;469-472.
29. Lewis J. Buprenorphine. Drug Alcohol Depend. 14:1985;363-372.
30. Mansour A., Fox C.A., Akil H., Watson J. Opioid-receptor mRNA expression in the rat CNS. anatomical and functional implications TINS. 18:1995;22-29.
31. Nakajima S. Subtypes of dopamine receptors involved in the mechanism of reinforcement. Neurosci. Biobehav. Rev. 13:1989;123-128.
32. Nakajima S., Baker J.D. Dopamine D2 receptor blockade with raclopride. effects on intracranial self-stimulation and food reinforced operant behaviour Psychopharmac. 98:1989;330-333. (Berlin).
33. Nakajima S., O'Regan N.B. The effects of dopaminergic agonists and antagonists on the frequency-response function for hypothalamic self-administration in the rat. Pharmac. Biochem. Behav. 39:1990;465-468.
34. Olds M.E. Reinforcing effects of morphine in the nucleus accumbens. Brain Res. 237:1982;429-440.
35. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A Stereotaxic Atlas of the Rat Brain. 2:1985;Plenum, New York and London.
36. Pettit H.O., Ettenberg A., Bloom F.E., Koob G.F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology. 84:1984;167-173.
37. Phillips A.G., LePiane F.G. Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmac. Biochem. Behav. 12:1980;965-968.
38. Sanger D.J. The actions of SCH 23390, a D1 receptor antagonist, on operant and avoidance behavior in rats. Pharmac. Biochem. Behav. 26:1987;509-513.
39. Schoener E.P., Elkins D.P. Neuronal response to dopamine in rat neostriatum. a push-pull perfusion study Neuropharmacology. 23:1983;611-616.
40. Shippenberg T.S., Herz A. Place preference conditioning reveals the involvement of D-1 dopamine receptors in the motivational properties of μ- and κ-opioid agonists. Brain Res. 436:1987;169-172.
41. Shippenberg T.S., Bals-Kubik R., Herz A. Examination of the neurochemical substrates mediating the effects of opioids. role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors J. Pharmac. Exp. Ther. 265:1992;53-59.
42. Smith J.E., Guerin G.F., Co C., Barr T.S., Lane J.D. Effects of 6-OHDA lesions of the central medial nucleus accumbens on rat intravenous morphine self-administration. Pharmac. Biochem. Behav. 23:1985;843-849.
43. Spangel R., Herz A., Bals-Kubic R., Shippenberg T.S. β-Endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology. 104:1991;51-56.
44. Spyraki C., Fibiger H.C., Phillips A.G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmac. 79(2-3):1983;278-283.
45. Stinus L., Nadaud D., Deminiere J.-M., Jauregui J., Hand T.T., Le Moal M. Chronic flupenthixol treatment potentiates the reinforcing properties of systemic heroin administration. Biol. Psychiatry. 26:1989;363-371.
46. Swanson L.W. The projections of the ventral tegmental area and adjacent regions. a combined fluorescent retrograde tracer and immunofluorescence study in the rat Brain Res. Bull. 9:1982;321-353.
47. Walker E.A., Zernig G., Woods J.H. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J. Pharmac. Exp. Ther. 273:1995;1345-1352.
48. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine. ceiling effects at high doses Clin. Pharmac. Ther. 55:1994;569-580.
49. Welzl H., Kuhn G., Huston J.P. Self-administration of small amounts of morphine through glass micropipettes into the ventral tegmental area of the rat. Neuropharmacology. 28:1989;1017-1023.
50. 2 dopamine receptors in the rat nucleus accumbens. J. Neurosci. 6:1986;274-280.
51. Yang C.R., Mogenson G.J. Electrophysiological responses of neurones in the nucleus accumbens to hippocampal stimulation of the excitatory responses by the mesolimbic dopaminergic system. Brain Res. 324(1):1984;69-84.